Patients' Preferences for Adjuvant Osimertinib in Non-Small-Cell Lung Cancer After Complete Surgical Resection: What Makes It Worth It to Patients?
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Patient preferences for adjuvant Osimertinib in EGFR-mutated Non-small-cell lung cancer (NSCLC) vary, with many prioritizing disease-free survival (DFS) benefit over uncertain overall survival (OS) data.
Area Of Science
- Oncology
- Clinical Trials
- Patient-Reported Outcomes
Background
- The ADAURA trial demonstrated adjuvant Osimertinib's efficacy in EGFR-mutated Non-small-cell lung cancer (NSCLC).
- Limited overall survival (OS) data at approval presents a challenge for treatment decisions.
- Patient preferences for adjuvant therapy are crucial, especially with incomplete long-term survival data.
Purpose Of The Study
- To investigate patient preferences for adjuvant Osimertinib in EGFR-mutated NSCLC.
- To assess the influence of disease-free survival (DFS) benefit versus OS benefit on treatment decisions.
- To explore patient thresholds for accepting adjuvant Osimertinib based on survival data and willingness to pay.
Main Methods
- A survey was administered to NSCLC patients considering adjuvant therapy at Roswell Park Comprehensive Cancer Center.
- Patients evaluated hypothetical scenarios regarding minimum OS and DFS benefits required to justify adjuvant Osimertinib.
- Analysis included willingness to pay for treatment and impact of demographic factors.
Main Results
- 51 NSCLC patients participated, with 56% requiring a 12-month OS benefit and 72% a 12-month DFS benefit to justify Osimertinib.
- 31% would forgo treatment despite a 10% OS increase, and 33% were unwilling to pay copayments even with a 10-year OS benefit.
- Patient preferences were influenced by employment, education, and willingness to pay.
Conclusions
- Patient preferences for adjuvant Osimertinib are diverse and not solely driven by OS data.
- Disease-free survival (DFS) benefit plays a significant role in patient decision-making.
- Shared decision-making is essential, considering individual patient factors and preferences.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.